Table 2.
Distribution of HPV genotypes included in the nonavalent HPV vaccine according to age groups in CIN3.
| HPV genotypes | <35 years n (%) | 35–44 years n (%) | ≥45 years n (%) | p value∗ |
|---|---|---|---|---|
| Sample size (79) | Sample size (75) | Sample size (50) | ||
| HPV-16 | 57 (72.2) | 54 (72.0) | 27 (54.0) | 0.047 |
| HPV-18 | 5 (6.3) | 6 (8.0) | 4 (8.0) | 0.697 |
| HPV-31 | 2 (2.5) | 7 (9.3) | 3 (6.0) | 0.303 |
| HPV-33 | 9 (11.4) | 5 (6.7) | 1 (2.0) | 0.044 |
| HPV-45 | 2 (2.5) | 2 (2.7) | 4 (8.0) | 0.148 |
| HPV-52 | 1 (1.3) | 2 (2.7) | 1 (2.0) | 0.713 |
| HPV-58 | 3 (3.8) | 1 (1.3) | 3 (6.0) | 0.624 |
∗Using the Cochran–Armitage test for trend. HPV: human papillomavirus; CIN: cervical intraepithelial neoplasia.